Palisade Bio, Inc. announced on July 31, 2025, that the China National Intellectual Property Administration has issued a Notice of Allowance for a patent covering PALI-2108. This patent, titled 'Gut Microbiota-Activated PDE4 Inhibitor Prodrug,' will cover claims on the composition of matter for PALI-2108 in China.
Once issued, the patent term is expected to extend into 2045, subject to extensions for regulatory approval. This strengthens the global intellectual property portfolio around PALI-2108, which is being developed for fibrostenotic Crohn’s disease (FSCD) and moderate to severe ulcerative colitis (UC).
The allowance in China is crucial for protecting long-term value in one of the world’s largest and fastest-growing pharmaceutical markets. This supports both the company's clinical and strategic objectives as it advances PALI-2108 through clinical development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.